Webinar: Thursday, 27 October 2022, 7:00 PM

Ixekizumab in the treatment of Psoriasis

You are cordially invited to join Specialist Forum and Prof Adam Reich for a discussion on the use of ixekuzumab, an injectable humanised monoclonal antibody, in the treatment of psoriasis. Ixekuzumab is indicated for the treatment of moderate-to-severe plaque psoriasis and is associated with rapid and high response rates.

This webinar is sponsored by Eli Lilly and is intended for South African-based doctors only.

Presented by
Rene Bosman

Rene Bosman

  • Editor: The Specialist Forum
Prof Adam Reich

Prof Adam Reich

  • Head of the Department of Dermatology

Prof Reich is Head of the Department of Dermatology, as well as the Director of the Institute of Medical Sciences, University of Rzeszow, Rzeszów, Poland. He is also the Secretary General of the Polish Dermatological Society and Vice-Chair of the Youth Forum of the Polish Dermatological Society.

He completed his PhD in 2006 at the University of Medicine, Wroclaw, Poland. He is a member of the European Society for Dermatology and Psychiatry, European Society of Dermatological Research, European Academy of Dermatology and Venereology (EADV), International Forum for the Study of Itch and International Society of Dermatology.

He acts as a Section Editor for Itch/Psychology of the Journal of the European Academy of Dermatology and Venereology and the Co-Chair of the Prurigo Nodularis EADV Task Force. He is the author and/or coauthor of 176 original articles, 128 reviews and 88 case reports. He was also awarded the Prof Zdzisław Ruszczak Award for the scientific activity in psoriasis.

187 professionals have already registered.

Days
:
Hours
:
Minutes
:
Seconds

Webinar Registration

By registering for this webinar, you agree to our Terms & Conditions.

New Media, a division of Media24 (PTY) Ltd., abides to all data and privacy requirements. To find out more about our Privacy Policy you can find it here: www.media24.com/group-privacy-portal.

Please Note: The names, surnames, email addresses and duration of attendance of all webinar participants will be shared for statistical purposes only, with the sponsor of this webinar. No delegate will be contacted by the sponsor with marketing or sales offers, and your information will not be shared with any third-parties.

Should you wish to receive further information on the webinar topic from our sponsor, please opt in above.

Visit the official COVID-19 government website to stay informed: sacoronavirus.co.za